GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...

If you’re 60 years of age or older, speak with your healthcare provider or pharmacist about getting vaccinated against RSV. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is the first ...

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV ...

此外，近日GSK公布其RSV疫苗在预防60岁以上老年人3年（3个完整流行季）的保护效力，累积保护效力为63%，然而却呈现显著的下降趋势——从第1年的83%到第2年的56%再到第3年的48%，而Arexvy的初始效力在三款疫苗中已是佼佼者。

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

Clearside Biomedical reported positive results from a Phase 2b trial of its tyrosine kinase inhibitor in patients with wet ...

This year's prestigious Nobel Prize in Chemistry has been awarded to David Baker, the director of the Institute for Protein ...